aibioBCYC Bicycle Therapeutics plc
Bicycle Therapeutics (BCYC) news
Top story · Aug 20, 2026 · SEC filing 8-K
Bicycle Therapeutics reports a leadership change
On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the “Board”) of Bicycle Therapeutics plc (the “Company”), as a member of the Board’s committees and as a member of the Company’s Clinical Advisory Board, effective immediately.
Latest Bicycle Therapeutics news
We have not published a story on Bicycle Therapeutics yet. When there is news, it will appear here.
What Bicycle Therapeutics does
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, fully synthetic short peptides constrained to form two loops, for diseases underserved by existing therapeutics. The company describes them as combining biologic-type pharmacology with the manufacturing and pharmacokinetic properties of a small molecule, and as excreted by the kidney rather than the liver. Its internal programs focus on oncology. The lead candidate, nuzefatide pevedotin (formerly BT5528), is a Bicycle Drug Conjugate targeting Ephrin type A receptor 2 (EphA2), evaluated in a Phase I/II trial in advanced solid tumors and a Phase II trial in recurrent metastatic pancreatic ductal adenocarcinoma. BT1702, a radioconjugate with a lead-212 payload targeting MT1-MMP, is in IND-enabling activities. In March 2026 the company reprioritized its clinical portfolio, deprioritizing zelenectide pevedotin, a Nectin-4 targeting conjugate, and announced a workforce reduction of approximately 30%. The company also collaborates with other biopharmaceutical companies in additional therapeutic areas.
| Product or program | What it is | Stage |
|---|---|---|
| nuzefatide pevedotin (BT5528) | Bicycle Drug Conjugate targeting EphA2 | Phase I/II in advanced solid tumors; Phase II in pancreatic cancer |
| zelenectide pevedotin | Bicycle Drug Conjugate targeting Nectin-4 in urothelial cancer | Phase II/III Duravelo-2, planned conversion to randomized Phase II |
| BT1702 | Bicycle Radioconjugate with a lead-212 payload targeting MT1-MMP | IND-enabling activities |
| BT7480 | Bicycle TICA molecule targeting Nectin-4 and agonizing CD137 | Phase I/II |
Bicycle Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $72.6 million | $35.3 million |
| Research and development | $240.3 million | $173.0 million |
| Net income (loss) | -$219.0 million | -$169.0 million |
| Cash from operations | -$249.7 million | -$164.7 million |
| Cash and equivalents | $628.1 million | $879.5 million |
Questions about Bicycle Therapeutics
What is the ticker symbol of Bicycle Therapeutics?
Bicycle Therapeutics plc trades under the ticker BCYC on NASDAQ.
Where is Bicycle Therapeutics listed?
Bicycle Therapeutics plc is listed on NASDAQ.
What is the SEC CIK of Bicycle Therapeutics?
The SEC Central Index Key (CIK) for Bicycle Therapeutics plc is 1761612. Its filings are on SEC EDGAR.
How many shares does Bicycle Therapeutics have outstanding?
30,043,486 shares as of 2023-05-01, per the cover page of its 10-Q filed 2023-05-04.
Which country or territory is Bicycle Therapeutics listed under?
Our directory records Bicycle Therapeutics plc under United Kingdom.
What does Bicycle Therapeutics do?
Our directory classifies Bicycle Therapeutics plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Bicycle Therapeutics?
The ISIN recorded for Bicycle Therapeutics plc is US0887861088.
Does aibio.space cover Bicycle Therapeutics?
aibio.space lists Bicycle Therapeutics plc among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Bicycle Therapeutics incorporated?
SEC records list its state or country of incorporation as X0.
What does Bicycle Therapeutics develop?
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, fully synthetic short peptides constrained to form two loops, for diseases underserved by existing therapeutics. The company describes them as combining biologic-type pharmacology with the manufacturing and pharmacokinetic properties of a small molecule, and as excreted by the kidney rather than the liver.
What is nuzefatide pevedotin (BT5528) from Bicycle Therapeutics?
nuzefatide pevedotin (BT5528): Bicycle Drug Conjugate targeting EphA2 Stage: Phase I/II in advanced solid tumors; Phase II in pancreatic cancer.
What is zelenectide pevedotin from Bicycle Therapeutics?
zelenectide pevedotin: Bicycle Drug Conjugate targeting Nectin-4 in urothelial cancer Stage: Phase II/III Duravelo-2, planned conversion to randomized Phase II.
What was Bicycle Therapeutics's revenue last year?
$72.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Bicycle Therapeutics profitable?
Bicycle Therapeutics plc reported a net loss of $219.0 million for the fiscal year ended Dec 31, 2025, and used $249.7 million of cash in operations, per its annual report to the SEC.
How much does Bicycle Therapeutics spend on research and development?
$240.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Bicycle Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Bicycle Therapeutics Plc
- CIK
- 1761612
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- BCYC (Nasdaq)
- State or country of incorporation
- X0
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, United Kingdom, CB21 6GS
- Phone
- 011441223261503
- Shares outstanding
- 30,043,486 as of 2023-05-01 (10-Q filed 2023-05-04)
- Former names
- BICYCLE THERAPEUTICS Ltd
Recent filings
Listing details
- Company
- Bicycle Therapeutics plc
- Ticker
- BCYC
- Listing
- NASDAQ
- Country or territory
- United Kingdom
- Business scope
- Pharmaceuticals: Major
- ISIN
- US0887861088
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction